"George Papanikolaou" General Hospital of Thessaloniki
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Porpodis, Konstantinos
BREATH, NCT06288516: BenRalizumab Effect on Airway Remodeling in Severe asTHma

Recruiting
4
45
Europe
Benralizumab 30 mg/ml, biological
Aristotle University Of Thessaloniki, Pulmonary Clinic, Aristotle University of Thessaloniki, Greece, Pulmonary Clinic, University of Ioannina, Pulmonary Clinic, Democritus University of Thrace, 2nd Pulmonary Clinic, Kapodistrian University of Athens, University Hospital of Crete, Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens, University Hospital of Patras
Asthma; Eosinophilic, Airway Remodeling
12/25
06/26
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma ().

Recruiting
3
790
Europe, RoW
CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant
Chiesi Farmaceutici S.p.A.
Asthma
07/25
09/25
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

Recruiting
3
412
Europe, Canada, US, RoW
Salbutamol HFA-134a, Salbutamol HFA-152a
GlaxoSmithKline
Asthma
04/25
04/25
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in Japan (based on MATINEE trial) for COPD
Active, not recruiting
3
806
Europe, Canada, Japan, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD
Pulmonary Disease, Chronic Obstructive
08/24
08/24
MESILICO, NCT04612556: Efficacy of Mepolizumab in Severe Asthmatics on a Long Term

Active, not recruiting
N/A
45
Europe
Mepolizumab 100 MG [Nucala], biological/vaccine
Aristotle University Of Thessaloniki, NHS Pulmonary Clinic G. Papanikolaou Hospital, Thessaloniki, Greece, Pulmonary Clinic of Army Hospital Thessaloniki Greece, Pulmonary Clinic, Democritus University of Thrace, Pulmonary Clinic, University of Ioannina, 1st Pulmonary Clinic, Kapodistrian University of Athens, 2nd Pulmonary Clinic, Kapodistrian University of Athens, NHS 7th Pulmonary Clinic, Sotiria Hospital, Athens
Asthma; Eosinophilic, Severe Asthma, Late-Onset Asthma
03/23
03/25
CALIOPI, NCT05708300: Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma

Recruiting
N/A
57
Europe
Mepolizumab 100 MG [Nucala], biologicals/vaccine
Aristotle University Of Thessaloniki, 1st ORL Department, AHEPA Hospital, Aristotle University of Thessaloniki, Department of Otorhinolaryngology, Head and Neck Surgery, George Papanikolaou Hospital, Department of Otorhinolaryngology, Democritus University of Thrace, Alexandroupolis, Department of Pulmonology, Democritus University of Thrace, Alexandroupolis, Respiratory Medicine Department, University of Ioannina, Faculty of Medicine, Department of Respiratory Medicine, National and Kapodistrian University of Athens, Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Department of Otolaryngology, Head and Neck Surgery, Sotiria General Hospital, Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens
Chronic Rhinosinusitis With Nasal Polyps, Asthma
03/26
03/27

Download Options